ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) from its SEC filings: 2025 revenue $829.4 million (+23258% vs the year before), net margin -0%, free cash flow $156.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $829.4 million |
| Revenue growth | +23258% |
| Net income | -$1.6 million |
| Net margin | -0.2% |
| Free cash flow | $156.9 million |
| Diluted EPS | $-0.01 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +171% |
| Cash | $69.4 million |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.